According to a new research report “Presbyopia Therapeutics – Epidemiology and Pipeline Analysis, 2020” published by Pharma Proff, presbyopia therapeutics currently exhibits a proliferating pipeline of 10 therapeutic candidates.

Presbyopia Therapeutics Pipeline Insights

Presbyopia is an age-related eye condition that causes visual impairment gradually. With the onset age of 40 years, presbyopia results in the loss of flexibility of the eye to visualize nearly placed objects. There are mainly five types of presbyopia namely, premature presbyopia, incipient presbyopia, absolute presbyopia, functional presbyopia, and nocturnal presbyopia. Incipient presbyopia is the earliest stage of the disease in which symptoms or clinical findings on the near vision effects are reported. Functional presbyopia occurs due to the gradual decline in accommodative amplitude. Absolute presbyopia is a progressive stage of functional presbyopia that occurs because of the continuous gradual decline in accommodation. Premature presbyopia occurs due to nutritional, environmental, drug-induced, or disease-related factors. Lastly, nocturnal presbyopia is a condition in which near vision difficulties result from an apparent decrease in the amplitude of accommodation in dim light.

Patients with presbyopia report symptoms such as difficulty in reading tiny prints, eyestrain, headache, and fatigue. The disease can be diagnosed by analyzing the patient’s ophthalmic history in addition to the family history. Other assessments include, binocular vision and accommodation testing, visual acuity testing, ocular health assessment, supplemental testing, refraction testing, and others.

As per the current scenario, no therapeutic drug has been approved for the treatment of presbyopia. However, a number of market players are actively developing therapeutic drug candidates in different stages of development for the treatment of this condition.

Insights on Pipeline Segments

According to the research, majority of drug candidates in the presbyopia therapeutics pipeline are being developed a single agent i.e. monotherapy, while the rest are being developed as a combination of two compounds.

Strategic Development Activities are Expected to Drive the Presbyopia Therapeutics Pipeline Advancements

Companies are actively involved in strategic development activities such as merger & acquisitions, collaboration, and licensing to gain a competitive edge in the market. For instance, in May 2020, AbbVie Inc., a research-based biopharmaceutical company, completed the acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. Through this acquisition, AbbVie Inc. expanded its revenue base and compliments its immunology and hematologic oncology position.

Similarly, in December 2016, Novartis AG entered into a definitive agreement for the acquisition of Encore Vision, Inc., a privately-held company, focused on the development of a novel treatment in presbyopia. This acquisition added a first-in-class disease modifying topical treatment for presbyopia to the Novartis AG’s ophthalmology pipeline, providing a potentially disruptive innovation to patients in a new therapeutic area of high unmet need and high prevalence.

Positive Clinical Results are Expected to Accelerate the Growth of Presbyopia Therapeutics Pipeline

In October 2019, ORASIS Pharmaceuticals Ltd. declared the topline clinical results from the Phase IIb clinical trial, assessing PresbiDrops for the treatment of patients with presbyopia. As per the results of the study, the drug demonstrated statistically significant improvement in distance-corrected near visual acuity (DCNVA) of a three-line or greater gain. In addition, PresbiDrops demonstrated an exceptional safety and tolerability profile.

Browse report overview with detailed TOC on "Presbyopia Therapeutics – Epidemiology and Pipeline Analysis, 2020" at:https://www.pharmaproff.com/report/presbyopia-therapeutics-pipeline-analysis

Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, ViewPoint Therapeutics Inc., Allergan plc, Eyenovia Inc., Cellix Bio Pvt. Ltd., ORASIS Pharmaceuticals Ltd., Ocuphire Pharma Inc., and Presbyopia Therapies LLC are the major companies involved in the development of drug candidates for the treatment of presbyopia.

Presbyopia Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Product Type
• By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of presbyopia. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, market estimation, attribute analysis, epidemiology, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the presbyopia therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to presbyopia.